Genomic data plays a pivotal role in drug development by identifying potential drug targets and mechanisms of resistance. For instance, BRCA1/2 mutations have led to the development of PARP inhibitors, a class of drugs used in treating certain types of breast and ovarian cancers. By understanding the genetic basis of cancer, researchers can develop more effective and targeted therapies.
